Life Science

Più recente

281 a 290 di 445
  • Interim injunctions in English pharmaceutical patent disputes Accesso limitato

    Articolo

    Ultima consultazione: 09 September 2010 / Inviato: 09 September 2010

    This article analyses in detail the grant of interim injunctions in pharmaceutical litigation in the UK

  • Accuracy of information under scrutiny following the pharma sector inquiry Accesso limitato

    Articolo

    Ultima consultazione: 30 July 2010 / Inviato: 30 July 2010

    European Commission issues statement of objections for allegedly incorrect and misleading information.

  • The Court of Justice limits DNA protection to performing its function Accesso limitato

    Articolo

    Ultima consultazione: 12 July 2010 / Inviato: 07 July 2010

    In its first decision on the infringement provisions of the Biotechnology Directive, the Court of Justice has given judgment in the case of Monsanto.

  • The law behind the headlines - The patenting of Synthetic Life Accesso limitato

    Articolo

    Ultima consultazione: 19 July 2010 / Inviato: 07 July 2010

    What are the science and patent issues behind the recent announcement by the J Craig Venter Institute (JCVI) that they have created a new life form?

  • Acting out of the ordinary in response to drug price cuts Accesso limitato

    Articolo

    Ultima consultazione: 22 June 2010 / Inviato: 22 June 2010

    The impact of Greece`s sovereign debt crisis on pharmaceutical pricing.

  • French competition authority ruling on hospital and pharmacy markets Accesso limitato

    Articolo

    Ultima consultazione: 21 June 2010 / Inviato: 21 June 2010

    The French Competition Authority rules in the low molecular weight heparins (LMWH) case on dominant position and provision at no charge policy.

  • EU Member State public health authorities may lawfully offer incentives to doctors Accesso limitato

    Articolo

    Ultima consultazione: 21 June 2010 / Inviato: 21 June 2010

    Rejecting Advocate General`s Jääskinen opinion, the Court of Justice of the EU has held that financial incentive schemes implemented by national public health authorities of Member States that encourage doctors to prescribe certain named medicines in preference to others in the same therapeutic class are not rendered unlawful by the European Medicines Directive.

  • Failure to control a subsidiary may lead to temporary suspension of business Accesso limitato

    Articolo

    Ultima consultazione: 21 June 2010 / Inviato: 21 June 2010

    A large Japanese pharmaceutical company has had its business suspended due to the inclusion of falsified data in a new product marketing authorisation application. Failure to control and integrate post merger organisation were indicated as possible causes.

  • First sentencing of a pharmaceutical company for violation of the anti gift law Accesso limitato

    Articolo

    Ultima consultazione: 21 June 2010 / Inviato: 21 June 2010

    The Criminal Court of Clermont-Ferrand rendered on 15 March 2010 a judgment in first instance against a French pharmaceutical company, imposing a fine on the company. This decision is the first sentencing of a pharmaceutical company in France for a violation of the anti gift law which prohibits pharmaceutical companies from granting any kind of benefits, directly or indirectly, to healthcare professionals.

  • VAT treatment of stem cell extraction and storage Accesso limitato

    Articolo

    Ultima consultazione: 11 June 2010 / Inviato: 11 June 2010

    The ECJ has concluded that the service of collecting, transporting, analysing and storing umbilical cord blood so that stem cells may be used for future treatment in the event of later disease does not fall within the scope of `closely related activities` to exempt hospital and medical care.

281 a 290 di 445